CaltechAUTHORS
  A Caltech Library Service

Gene Expression Profiles as Predictors of Poor Outcomes in Stage II Colorectal Cancer: A Systematic Review and Meta-analysis

Lu, An-Ting T. and Salpeter, Shelley R. and Reeve, Anthony E. and Eschrich, Steven and Johnston, Patrick G. and Barrier, Alain J. and Bertucci, Francois and Buckley, Nicholas S. and Salpeter , Edwin E. and Lin, Albert Y. (2009) Gene Expression Profiles as Predictors of Poor Outcomes in Stage II Colorectal Cancer: A Systematic Review and Meta-analysis. Clinical Colorectal Cancer, 8 (4). pp. 207-214. ISSN 1533-0028. https://resolver.caltech.edu/CaltechAUTHORS:20100618-144605206

[img] PDF - Published Version
Restricted to Repository administrators only
See Usage Policy.

1494Kb

Use this Persistent URL to link to this item: https://resolver.caltech.edu/CaltechAUTHORS:20100618-144605206

Abstract

Purpose: The use of adjuvant therapy in stage II colorectal cancer (CRC) remains controversial. There is a need to identify more effective predictors than the traditional staging system to aid therapeutic decision-making. We performed a systematic review and meta-analysis of gene expression profiles (GEPs) to assess their utility for risk stratification and prediction of poor outcomes in stage II CRC. Patients and Methods: We performed a comprehensive literature search through December 2007. Studies were included if they reported GEP-based assays in patients with stage II CRC, and either subsequent cancer recurrence or death within 3 years. The prognostic likelihood ratio (LR) and odds ratio (OR) were calculated with 95% confidence intervals and pooled using the fixed-effects method. The weighted average sensitivity, specificity, and accuracy were also reported. Results: Eight cohorts involving 271 patients contributed to the analysis. The average accuracy, sensitivity, and specificity were 81.9%, 76.2%, and 84.5%, respectively, with a prognostic LR of 4.7 (95% CI, 3.2-6.8) and a prognostic OR of 15.1 (95% CI, 7.9-28.6). No evidence for significant interstudy heterogeneity was noted in either analysis. Subgroup analysis found no difference in results for the prediction of cancer recurrence or death. Conclusion: This analysis demonstrates the promising potential of using GEP assays as predictors of poor outcomes in stage II CRC, such as cancer recurrence or death. To maximize their utility and availability, further studies will be needed to identify and validate specific gene signatures for poor prognosis in stage II CRC.


Item Type:Article
Related URLs:
URLURL TypeDescription
http://dx.doi.org/10.3816/CCC.2009.n.035 DOIUNSPECIFIED
http://cigjournals.metapress.com/content/v33n60816315212q/PublisherUNSPECIFIED
Additional Information:© 2009 CIG Media Group, L.P. Submitted: Aug 22, 2008; Revised: Oct. 23, 2008; Accepted: Oct. 27, 2008.
Funders:
Funding AgencyGrant Number
Valley Foundation UNSPECIFIED
Subject Keywords:DNA microarray, Gene signature, Likelihood ratio, Prognosis prediction
Issue or Number:4
Record Number:CaltechAUTHORS:20100618-144605206
Persistent URL:https://resolver.caltech.edu/CaltechAUTHORS:20100618-144605206
Official Citation:Lu, A.-T., S. Salpeter, et al. (2009). "Gene Expression Profiles as Predictors of Poor Outcomes in Stage II Colorectal Cancer: A Systematic Review and Meta-analysis." Clinical Colorectal Cancer 8(4): 207-214. doi:10.3816/CCC.2009.n.035
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:18738
Collection:CaltechAUTHORS
Deposited By: Tony Diaz
Deposited On:06 Aug 2010 21:36
Last Modified:03 Oct 2019 01:47

Repository Staff Only: item control page